Download presentation
Presentation is loading. Please wait.
1
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Prof Nicholas D James, PhD, Matthew R Sydes, MSc, Prof Noel W Clarke, ChM, Prof Malcolm D Mason, MD, Prof David P Dearnaley, MD, Melissa R Spears, MSc, Alastair W S Ritchie, MD, Christopher C Parker, MD, J Martin Russell, FRCR, Gerhardt Attard, MD PhD, Prof Johann de Bono, PhD, William Cross, PhD, Prof Rob J Jones, PhD, Prof George Thalmann, MD, Claire Amos, PhD, David Matheson, PhD, Robin Millman, Mymoona Alzouebi, FRCR, Sharon Beesley, FRCR, Alison J Birtle, MD, Susannah Brock, FRCR, Richard Cathomas, MD, Prabir Chakraborti, FRCR, Simon Chowdhury, MD, Audrey Cook, FRCR, Tony Elliott, PhD, Joanna Gale, DM, Stephanie Gibbs, FRCR, John D Graham, FRCP, John Hetherington, FRCS[Eng], Robert Hughes, FRCR, Robert Laing, FRCR, Fiona McKinna, FRCR, Duncan B McLaren, FRCR, FRCP[Ed], Prof Joe M O'Sullivan, MD, Omi Parikh, FRCR, Clive Peedell, FRCR, Andrew Protheroe, PhD, Angus J Robinson, FRCR, Narayanan Srihari, MD, Rajaguru Srinivasan, FRCR, John Staffurth, MD, Santhanam Sundar, FRCR, Shaun Tolan, MD, David Tsang, MCRP, Prof John Wagstaff, MD, Prof Mahesh K B Parmar, DPhil The Lancet Volume 387, Issue 10024, Pages 1163-1177 (March 2016) DOI: 10.1016/S0140-6736(15)01037-5 Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY Terms and Conditions Terms and Conditions
![Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Prof Nicholas D James, PhD, Matthew R Sydes, MSc, Prof Noel W Clarke, ChM, Prof Malcolm D Mason, MD, Prof David P Dearnaley, MD, Melissa R Spears, MSc, Alastair W S Ritchie, MD, Christopher C Parker, MD, J Martin Russell, FRCR, Gerhardt Attard, MD PhD, Prof Johann de Bono, PhD, William Cross, PhD, Prof Rob J Jones, PhD, Prof George Thalmann, MD, Claire Amos, PhD, David Matheson, PhD, Robin Millman, Mymoona Alzouebi, FRCR, Sharon Beesley, FRCR, Alison J Birtle, MD, Susannah Brock, FRCR, Richard Cathomas, MD, Prabir Chakraborti, FRCR, Simon Chowdhury, MD, Audrey Cook, FRCR, Tony Elliott, PhD, Joanna Gale, DM, Stephanie Gibbs, FRCR, John D Graham, FRCP, John Hetherington, FRCS[Eng], Robert Hughes, FRCR, Robert Laing, FRCR, Fiona McKinna, FRCR, Duncan B McLaren, FRCR, FRCP[Ed], Prof Joe M O Sullivan, MD, Omi Parikh, FRCR, Clive Peedell, FRCR, Andrew Protheroe, PhD, Angus J Robinson, FRCR, Narayanan Srihari, MD, Rajaguru Srinivasan, FRCR, John Staffurth, MD, Santhanam Sundar, FRCR, Shaun Tolan, MD, David Tsang, MCRP, Prof John Wagstaff, MD, Prof Mahesh K B Parmar, DPhil The Lancet Volume 387, Issue 10024, Pages (March 2016) DOI: /S (15) Copyright © 2016 James et al.](http://images.slideplayer.com./37/10696934/slides/slide_1.jpg "Open Access article distributed under the terms of CC BY Terms and Conditions Terms and Conditions.")
2
Figure 1 The Lancet 2016 387, 1163-1177DOI: (10.1016/S0140-6736(15)01037-5) Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY Terms and Conditions Terms and Conditions
3
Figure 2 The Lancet 2016 387, 1163-1177DOI: (10.1016/S0140-6736(15)01037-5) Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY Terms and Conditions Terms and Conditions
4
Figure 3 The Lancet 2016 387, 1163-1177DOI: (10.1016/S0140-6736(15)01037-5) Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY Terms and Conditions Terms and Conditions
5
Figure 4 The Lancet 2016 387, 1163-1177DOI: (10.1016/S0140-6736(15)01037-5) Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY Terms and Conditions Terms and Conditions
Similar presentations
